KR20100093046A - 응고 인자 ｖｉｉａ 조절물질의 제조, 조성물 및 용도 - Google Patents

응고 인자 ｖｉｉａ 조절물질의 제조, 조성물 및 용도 Download PDF

Info

Publication number
KR20100093046A
KR20100093046A KR1020107010696A KR20107010696A KR20100093046A KR 20100093046 A KR20100093046 A KR 20100093046A KR 1020107010696 A KR1020107010696 A KR 1020107010696A KR 20107010696 A KR20107010696 A KR 20107010696A KR 20100093046 A KR20100093046 A KR 20100093046A
Authority
KR
South Korea
Prior art keywords
composition
formula
compound
solution
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107010696A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 로우리
노버트 퍼로
Original Assignee
파마시클릭스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파마시클릭스, 인코포레이티드 filed Critical 파마시클릭스, 인코포레이티드
Publication of KR20100093046A publication Critical patent/KR20100093046A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107010696A 2007-10-16 2008-10-16 응고 인자 ｖｉｉａ 조절물질의 제조, 조성물 및 용도 Ceased KR20100093046A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98038607P 2007-10-16 2007-10-16
US60/980,386 2007-10-16

Publications (1)

Publication Number Publication Date
KR20100093046A true KR20100093046A (ko) 2010-08-24

Family

ID=40568072

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107010696A Ceased KR20100093046A (ko) 2007-10-16 2008-10-16 응고 인자 ｖｉｉａ 조절물질의 제조, 조성물 및 용도

Country Status (9)

Country Link
US (3) US8552046B2 (enExample)
EP (2) EP2586794A3 (enExample)
JP (2) JP5733744B2 (enExample)
KR (1) KR20100093046A (enExample)
CN (2) CN101861335B (enExample)
CA (1) CA2702970A1 (enExample)
EA (2) EA201370191A1 (enExample)
ES (1) ES2403413T3 (enExample)
WO (1) WO2009052323A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1569912E (pt) 2002-12-03 2015-09-15 Pharmacyclics Llc Derivados 2-(2-hidroxibifenil-3-il)-1h-benzoimidazole-5- carboxamidina como inibidores do fator viia
CA2569163A1 (en) 2004-06-02 2005-12-15 Pharmacyclics, Inc. Factor viia inhibitor
US8729117B2 (en) 2004-06-02 2014-05-20 Pharmacyclics, Inc. Factor VIIa inhibitor
EP2586794A3 (en) 2007-10-16 2013-07-17 Pharmacyclics, Inc. Manufacture, Compositions and Uses of Coagulationfactor VIIA Modulator
WO2012142317A1 (en) * 2011-04-15 2012-10-18 Gamma Therapeutics, Inc Fast-clotting wound dressings
US8980823B2 (en) 2012-03-07 2015-03-17 Shaker A. Mousa Formulations of Factor VIIa inhibitors and utility
AP2014008049A0 (en) 2012-04-16 2014-11-30 Cantab Biopharmaceuticals Patents Ltd Optimised subcuraneous therapeutic agents
EP3016646A4 (en) * 2013-07-05 2017-03-01 Shaker A. Mousa NOVEL FORMULATIONS OF FACTOR VIIa INHIBITORS AND UTILITY
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
CA2962768C (en) * 2014-10-01 2023-10-10 Alyssa M. Larson Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
RU2641058C1 (ru) * 2016-11-17 2018-01-15 федеральное государственное автономное образовательное учреждение высшего образования "Российский университет дружбы народов" (РУДН) Способ профилактики венозной тромбоэмболии у больных раком шейки матки
CN109627218B (zh) * 2018-11-27 2022-03-29 深圳市龙华区中心医院 一种抗凝小分子化合物及其应用和包含其的药物
CN116283896B (zh) * 2022-09-07 2024-10-29 广东晨康生物科技有限公司 一种具有pd-l1抑制活性的联苯类化合物及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
RU2093176C1 (ru) * 1992-12-16 1997-10-20 Левон Никитович Мкртчян Способ лечения рака молочной железы и рака тела матки
EP1140859A2 (en) 1998-12-18 2001-10-10 Axys Pharmaceuticals, Inc. (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
US20020037912A1 (en) 2000-08-11 2002-03-28 Leahy Ellen M. Factor viia inhibitors
US6465503B2 (en) 2000-08-11 2002-10-15 Axys Pharmaceuticals, Inc. Selective urokinase inhibitors
EP1449555B1 (en) * 2001-03-23 2006-06-21 Novo Nordisk A/S Needle cannula
WO2003006011A1 (en) 2001-07-09 2003-01-23 Axys Pharmaceuticals, Inc. 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
WO2003068756A1 (en) 2002-02-13 2003-08-21 Axys Pharmaceuticals, Inc. 2-[5-(5-carbamimidoyl-1h-heteroaryl)]-6-hydroxybiphenyl-3-yl derivatives as factor viia inhibitors
JP5188003B2 (ja) 2002-04-08 2013-04-24 エーザイ インコーポレイテッド プロポフォールの水溶性プロドラッグを含む薬学的組成物およびその投与方法
PT1569912E (pt) 2002-12-03 2015-09-15 Pharmacyclics Llc Derivados 2-(2-hidroxibifenil-3-il)-1h-benzoimidazole-5- carboxamidina como inibidores do fator viia
WO2004062661A1 (en) * 2003-01-08 2004-07-29 Axys Pharmaceuticals, Inc. 2-‘5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl!- carboxylic acid derivatives as factor viia inhibitors
CA2569163A1 (en) * 2004-06-02 2005-12-15 Pharmacyclics, Inc. Factor viia inhibitor
CN1976903A (zh) * 2004-06-02 2007-06-06 法莫西克立克斯公司 因子VⅡa抑制剂
EP2586794A3 (en) 2007-10-16 2013-07-17 Pharmacyclics, Inc. Manufacture, Compositions and Uses of Coagulationfactor VIIA Modulator
US20110299806A1 (en) * 2010-06-08 2011-12-08 Leonid Kashchenevsky Spindle, shaft supporting device and method of supporting a rotatable shaft

Also Published As

Publication number Publication date
CN103705507A (zh) 2014-04-09
EP2209801A2 (en) 2010-07-28
HK1147267A1 (en) 2011-08-05
EP2209801A4 (en) 2011-04-06
EA019258B1 (ru) 2014-02-28
EP2586794A3 (en) 2013-07-17
WO2009052323A3 (en) 2009-09-11
JP2015157830A (ja) 2015-09-03
JP2011500717A (ja) 2011-01-06
US20130158089A1 (en) 2013-06-20
WO2009052323A2 (en) 2009-04-23
EP2209801B1 (en) 2013-01-16
ES2403413T3 (es) 2013-05-17
EP2586794A2 (en) 2013-05-01
CA2702970A1 (en) 2009-04-23
JP5733744B2 (ja) 2015-06-10
US8748468B2 (en) 2014-06-10
EA201000633A1 (ru) 2011-04-29
EA201370191A1 (ru) 2014-05-30
US20100298396A1 (en) 2010-11-25
CN101861335A (zh) 2010-10-13
CN101861335B (zh) 2013-09-04
US8552046B2 (en) 2013-10-08
US20140039022A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
JP5733744B2 (ja) 凝血因子ＶＩＩａモジュレーターの製造、組成物及び使用
JP2016512549A (ja) ブルトン型チロシンキナーゼ阻害剤及びｃｙｐ３ａ４阻害剤の組み合わせ
KR20230007359A (ko) 메닌 억제제 및 cyp3a4 억제제의 조합물 및 그의 사용 방법
US10570124B2 (en) Deoxycytidine kinase binding compounds
JP2018503610A (ja) Ｂｔｋ阻害剤の組み合わせ及び投与レジメン
US20250269109A1 (en) Apparatus for and method in direct drug infusion using a label as a hanger
CN108024996A (zh) 布鲁顿氏酪氨酸激酶抑制剂组合和其用途
JP2018525411A (ja) 多発性骨髄腫を治療するためのｂｔｋ阻害剤の組み合わせ
DK202100115Y3 (da) Apparat til medicinlevering på plejestedet
TW202233613A (zh) 去氧胞苷激酶抑制劑之結晶型及其用途
HK1181783A (en) Manufacture, compositions and uses of coagulationfactor viia modulator
HK1147267B (en) Manufacture, compositions and uses of coagulationfactor viia modulator
EA042997B1 (ru) Комбинированная терапия рака ингибитором hdac и ингибитором pd-l1

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100514

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131015

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150217

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151030

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150217

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20151211

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20160201

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20151030

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2016101000616

Request date: 20160201

J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

Appeal kind category: Appeal against decision to decline refusal

Request date: 20160201

Appeal identifier: 2016101000616